AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35810277
Drug: Cefixime (CFM)
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime (CFM) 800 mg oral + Doxycycline (DOX)
Trial: 33957004
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds oil (2.5 ml twice daily for 8 weeks)
Trial: 32951358
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg or 10 mg/kg for body weight <30 kg; 8 mg/kg for body weight ≥30 kg) administered intravenously every 4 weeks for 16 weeks, followed by random assignment to tocilizumab or placebo.
Trial: 34597729
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 (VDZ)
Trial: 34597729
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 plus an additional dose at week 10 (VDZ + wk10)
Trial: 34406312
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) users
Trial: 34406312
Drug: Prophylactic-dose LMWH
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic-dose LMWH users
Trial: 34406312
Drug: Intermediate-dose LMWH
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose LMWH users (based on biomarkers)
Trial: 34406312
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of anticoagulants
Trial: 32757418
Drug: Sweet-tasting solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet-tasting solution
Trial: 34271362
Drug: Duloxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (40 mg BID) + innovative pelvic floor muscle training (iPFMT) with lumbopelvic stabilization
Trial: 34271362
Drug: Oral duloxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral duloxetine treatment (40 mg BID)
Trial: 32253184
Drug: Bimekizumab 16
RxNorm normalized name: Bimekizumab 160 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 16 mg
Trial: 35379598
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg intravenous tocilizumab (Group 1)
Trial: 35379598
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg intravenous tocilizumab (Group 2)
Trial: 35379598
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of intravenous tocilizumab
Trial: 33454995
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptives (COCs)
Trial: 34044355
Drug: I-Gel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-Gel®
Trial: 35046189
Drug: Intermaxillary fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermaxillary fixation (IMF) screw therapy
Trial: 35046189
Drug: Placebo (intraarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intraarticular saline injection)
Trial: 32173375
Drug: gp120 trimers
RxNorm normalized name: glyoxal trimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120 trimers bound to BLPs delivered via intranasal (i.n.) drip
Trial: 33131314
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP <120 mm Hg)
Trial: 34528337
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (7 days of omeprazole + amoxicillin followed by 7 days of omeprazole + clarithromycin + metronidazole)
Trial: 36478192
Drug: Active distraction
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active distraction using video games on a tablet device and wireless joystick (VG)
Trial: 36478192
Drug: Passive distraction
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive distraction using video on tablet and wireless headphones (AV)
Trial: 33169240
Drug: Citicoline 10
RxNorm normalized name: citicoline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 10 mg/kg/12h IV for 6 weeks plus supportive measures
Trial: 32455493
Drug: Prehydration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehydration with 1.5 L of water within 1 hour before uroflowmetry
Trial: 32103603
Drug: Autologous skin
RxNorm normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous skin cell suspension (ASCS) + compression therapy
Trial: 32103603
Drug: Standard compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard compression therapy (Control)
Trial: 615704460
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of ALA administered to recipients and graft perfused with 600 mg of ALA 1 hour before surgery
Trial: 38293957
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg
Trial: 35920936
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg ICG
Trial: 35920936
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg ICG
Trial: 35920936
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg ICG
Trial: 35920936
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ICG
Trial: 35655234
Drug: 6% Hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Hydroxyethyl Starch (HES) 130 solution (Volulyte 6%)
Trial: 35655234
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution (Ionolyte)
Trial: 35308505
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 3000 IU/d oral spray supplementation
Trial: 33620551
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of a multivitamin tablet with 150 μg of iodine
Trial: 33620551
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of a multivitamin tablet without iodine
Trial: 32980142
Drug: Norepinephrine 5 μg.mL−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5 μg.mL−1 (n = 40)
Trial: 32980142
Drug: Epinephrine 5 μg.mL−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 5 μg.mL−1 (n = 40)
Trial: 32980142
Drug: Phenylephrine 100 μg.mL−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 μg.mL−1 (n = 40)
Trial: 32980142
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusions (n = 40)
Trial: 34561142
Drug: Engerix-B vaccine
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B vaccine
Trial: 35771219
Drug: Home-based leg
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based leg heat therapy (HT) using water-circulating trousers, 90 min/session, 7 days/week for 8 weeks
Trial: 34154590
Drug: Relugolix 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix 10 mg
Trial: 34154590
Drug: Relugolix 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix 20 mg
Trial: 34154590
Drug: Relugolix 40
RxNorm normalized name: relugolix 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix 40 mg
Trial: 34154590
Drug: Leuprorelin 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 3.75 mg
Trial: 36178636
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step count
Trial: 34989637
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a tourniquet and buffered lidocaine solution (CTB)
Trial: 34496924
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical treatment (control group)
Trial: 34015311
Drug: Neoadjuvant durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant durvalumab monotherapy
Trial: 34953451
Drug: Swedish massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish massage (30-min sessions, twice a week for first 4 weeks, three times a week for last 4 weeks)
Trial: 32989866
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment once a week (Group 1)
Trial: 32989866
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment twice a week (Group 2)
Trial: 32989866
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy once a week (Group 3)
Trial: 34031890
Drug: Prednisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (50 mg for 7 days)
Trial: 33992438
Drug: Saccharomyces cerevisiae
RxNorm normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6)
Trial: 33992438
Drug: Chinese hamster
RxNorm normalized name: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6)
Trial: 33992438
Drug: Saccharomyces cerevisiae
RxNorm normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6)
Trial: 32602970
Drug: TARC-2 >800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARC-2 >800 pg/mL
Trial: 32602970
Drug: TARC-2 ≤800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARC-2 ≤800 pg/mL
Trial: 32602970
Drug: TARC-2 >800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARC-2 >800 pg/mL (whole study population)
Trial: 32602970
Drug: TARC-2 >800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARC-2 >800 pg/mL (PET-2-negative patients)
Trial: 36281170
Drug: Low-dose doxepin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxepin (6.25 mg-12.5 mg per day) for 12 weeks
Trial: 33518123
Drug: Temperature/RH combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature/RH combination of -15°C with uncontrolled RH for 8 hours
Trial: 33518123
Drug: Temperature/RH combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature/RH combination of 30°C with 80% RH for 8 hours
Trial: 33518123
Drug: Temperature/RH combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature/RH combination of 30°C with 30% RH for 8 hours
Trial: 35446986
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for PTSD
Trial: 35446986
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for PTSD and depression
Trial: 35676030
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid (ω3FA) supplementation (4 g/day)
Trial: 35676030
Drug: No ω3FA
RxNorm normalized name: NO
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No ω3FA treatment (Control)
Trial: 33966671
Drug: 1‐minute ultraviolet‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐minute ultraviolet‐C light (UV‐C) treatment prior to donning
Trial: 32998766
Drug: Ferritin-guided donation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin-guided donation intervals policy (including ferritin measurements for all new donors and at every 5th whole blood donation, extending donation intervals to 6 months if ferritin is 15-≤ 30 ng/mL and to 12 months if ferritin is < 15 ng/mL)
Trial: 35334862
Drug: High-dose whey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose whey protein concentrate (WPC)
Trial: 38777128
Drug: Tirzepatide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (all doses)
Trial: 36104378
Drug: Luseogliflozin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (2.5 mg daily)
Trial: 36104378
Drug: Voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.6 mg daily)
Trial: 35418599
Drug: Selenite 6
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 6 mg/l
Trial: 35418599
Drug: Selenite 8
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 8 mg/l
Trial: 35418599
Drug: Selenite 10
RxNorm normalized name: sodium selenite 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 10 mg/l
Trial: 35418599
Drug: Nano-selenium 12
RxNorm normalized name: selenious acid
DrugBank: Selenious acid (DB11127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-selenium 12 mg/l
Trial: 35418599
Drug: Selenite 6
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite 6 mg/l and 8 mg/l
Trial: 34022796
Drug: Vonoprazan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan (20 mg/day)
Trial: 34022796
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg/day)
Trial: 32031904
Drug: HIV patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV patients accessing antiretroviral treatment
Trial: 35768650
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W)
Trial: 33567129
Drug: Raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (3 mg/m2 from day 1 every 3 weeks) and oral S‐1 (80‐120 mg for 14 days every 3 weeks)
Trial: 35666800
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg of 0.1% E2 gel daily
Trial: 36951827
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg once daily
Trial: 35031887
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (415 mg)
Trial: 34238546
Drug: Haemodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemodynamic therapy to achieve individualised preoperative DO2
Trial: 35303025
Drug: Higher initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher initial levels of other drug use
Trial: 34812863
Drug: Intra-articular Platelet-Rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Platelet-Rich Plasma (PRP) injections (n=144 participants)
Trial: 34812863
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo injections (n=144 participants)
Trial: 34475964
Drug: Qishen Yiqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi dripping pills (QSYQ) for 12 weeks
Trial: 32275024
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural (TEA) with 0.25% bupivacaine and continuous infusion of 0.1% bupivacaine with 2 mcg/ml of fentanyl.
Trial: 32275024
Drug: Intercostal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal block (ICN) with 0.25% bupivacaine and continuous intravenous morphine infusion of 0.015‐0.02 mg/kg/hr.
Trial: 34020205
Drug: Active iTBS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active iTBS (1200 pulses per session, twice daily over ten weekdays)
Trial: 35727095
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily for 4 weeks followed by 40 mg for 8 weeks
Trial: 35727095
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg for 4 weeks followed by 20 mg for 8 weeks
Trial: 34314906
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intravenous granisetron
Trial: 34314906
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml normal saline (placebo)
Trial: 35246123
Drug: Biologics (mepolizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics (mepolizumab, benralizumab, dupilumab)
Trial: 34528335
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) referral volume from PSCs
Trial: 33419469
Drug: New experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New experimental therapy
Trial: 32743954
Drug: Prucalopride 4
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prucalopride 4 mg daily
Trial: 32162274
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate 250 mg BID
Trial: 32162274
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg QD
Trial: 36170688
Drug: Low-dose glucocorticoids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucocorticoids (dexamethasone 8 mg)
Trial: 32809976
Drug: HRZE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRZE treatment
Trial: 32809976
Drug: Ineffective therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineffective therapy
Trial: 32748293
Drug: Clazosentan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (20 mg/h i.v. for 3 h)
Trial: 32748293
Drug: Clazosentan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (60 mg/h i.v. for 3 h)
Trial: 32748293
Drug: Moxifloxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (single oral dose of 400 mg)
Trial: 33957025
Drug: 1.0% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% hydrogen peroxide mouthwash and 0.5% hydrogen peroxide nasal spray for 7 days
Trial: 35848045
Drug: Robot‐assisted mirror
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot‐assisted mirror therapy (RMT)
Trial: 35848045
Drug: Standard mirror
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard mirror therapy (MT)
Trial: 33676601
Drug: Chemotherapy (capecitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)
Trial: 34618367
Drug: Topical Cyperus
RxNorm normalized name: Cyperus rotundus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cyperus rotundus essential oil (CREO)
Trial: 34618367
Drug: Placebo (cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cold cream)
Trial: 33129289
Drug: Prednisolone 10
RxNorm normalized name: prednisolone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 10 mg
Trial: 34316231
Drug: Intrauterine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine administration of 500 IU hCG (0.5 ml) before IUI
Trial: 34316231
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 0.5 ml of normal saline before IUI
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (5 μg each, two doses, administered intramuscularly, 21 days apart)
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (one dose on day 1)
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (two doses on day 1 and 21)
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (two doses on day 1 and 21) for subjects aged ≥50 years
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (one dose on day 1) for subjects aged ≥50 years
Trial: 34414368
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (after second dose)